Surv BioPharma Inc.


Our Business

Our Core Strengths

Proprietary technology platform for producing optimal therapeutic viruses

By applying our proprietary technology platform—“technology for constructing conditionally-replicating adenvovirus regulated with multiple tumor-specific factors (m-CRA)”—sequences involved in gene expression (e.g., promoters, therapeutic transgenes, adenovirus genes) can be separated into different genetic elements, and then introduced into m-CRA plasmids, thus enabling efficient construction of optimal therapeutic viruses within a short time period. Our therapeutic viruses are therefore optimized in terms of their constituent genetic elements.